Klinik protokol Az ərbaycan Respublikas
Yüklə 0,77 Mb.
|
|
Ədəbiyyat:
1. Arterial hipertenziyanın diaqnostika və müalicəsi üzrə klinik protokol. Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2009. - 64 səh. 2. Kəskin koronar sindromun diaqnostika və müalicəsi üzrə klinik protokol. Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2012. - 60 səh. 3. Sabit stenokardiyanın diaqnostika və müalicəsi üzrə klinik protokol. Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2009 - 48 səh. 4. Şəkərli diabet (tip 2) xəstəliyinin diaqnostika və müalicəsi üzrə klinik protokol. Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2009. - 36 səh. 5. Tütünçəkmədən imtina etmə üzrə klinik protokol. Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2012. - 44 səh. 6. Ürək çatışmazlığının diaqnostika və müalicəsi üzrə klinik protokol. Azərbaycan Respublikasının Səhiyyə Nazirliyi. - Bakı, 2010. - 64 səh. 7. Albert M.A., Glynn R.J., Buring J., Ridker P.M. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation - 2006. 114:2619-2626. 8. Amarenco P, LabreucheJ. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. - 2009. 8:453-463. 9. American Association of Cardiovascular & Pulmonary Rehabilitation. Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs. Champaign, IL: Human Kinetics. - 2004. 10. American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and Prescription. 8th ed. Baltimore, MD: Lippincott, Williams and Wilkins. - 2009. 11. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. - 2002. - 324:71-86. 12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. - 1996. - 348:1329-1339. 13. Astrup A., Dyerberg J., Elwood P., Hermansen K., Hu F.B., Jakobsen M.U., et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr. - 2011. 93:684-688.
Klinik protokol Az ərbaycan Respublikas ı S əhiyy
ə Nazirliyinin İctimai S əhi yy
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 65 14. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev. - 2007. - 4: CD000123. 15. Baigent C, Blackwell L, Emberson J, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. - 2009. - 373:1849-1860. 16. Baigent C, Blackwell L, Emberson J, Holland LE, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. - 2010. - 376:1670-1681. 17. Balady G.J., Williams M.A., Ades P.A., Bittner V., Comoss P., Foody J.M., et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. - 2007. - 115:2675-2682. 18. Berger J.S., Jordan C.O., Lloyd-Jones D., Blumenthal R.S. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol. - 2010. - 55:1169-1177. 19. Billman G.E. Cardiac autonomic neural remodeling and susceptibility to sudden cardiac death: effect of endurance exercise training. Am J Physiol Heart Circ Physiol. - 2009. 297:H1171-H1193. 20. Bjarnason-Wehrens B., Grande G., Loewel H., Voller H., Mittag O. Genderspecific i ssues in cardiac rehabilitation: do women with ischemic heart 304. // Verschuren W.M., Jacobs D.R., Bloemberg B.P., Kromhout D., et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year followup of the seven countries study. JAMA. - 1995. 274:131-136. 21. Blackburn D.F., Lamb D.A., Eurich D.T., Johnson J.A., Wilson T.W., et al. Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. J Hypertens. - 2007. 25:1499-1505. 22. Boffetta P., Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ. - 2009. 339: b3060. 23. Borjesson M., Urhausen A., Kouidi E., Dugmore D., Sharma S., et al. Cardiovascular evaluation of middle-aged/senior individuals engaged in
Klinik protokol Az ərbaycan Respublikas ı S
əhiyy ə Nazirliyinin İctimai S əhi
yy ə v
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 66 leisure-time sport activities: position stand from the sections of exercise physiology and sports cardiology of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. - 2011. 18: 446-458. 24. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. - 2009. - 338:b2376. 25. Byington RP, Davis BR, Plehn JF, White HD, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. - 2001. - 103:387-392. 26. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. - 2008. 3: CD006103. 27. Center for Disease Control and Prevention [Electronic resource]: How Tobacco Smoke Causes Disease: The Biology and Behavioural Basis for Smoking-attributable Disease. A Report of the Surgeon General. - 2010.
- Availabe at: http://www.surgeongeneral.gov/library/ tobaccosmoke/index.html (12.02.2014). 28. Chandola T., Britton A., Brunner E., Hemingway H., Malik M., Kumari M., Badrick E., Kivimaki M., Marmot M. Work stress and coronary heart disease: what are the mechanisms? Eur Heart J. - 2008. 29:640-648. 29. Chen ZM, Jiang LX, Chen YP, Xie JX, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. - 2005. - 366:1607-1621. 30. Chida Y., Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol. - 2009. 53:936-946. 31. Claesson M., Birgander L.S., Lindahl B., Nasic S., Astrom M., Asplund K., Burell G. Women’s hearts-stress management for women with ischemic heart disease:explanatory analyses of a randomized controlled trial. J Cardiopulm Rehabil. - 2005. 25:93-102. 32. Clark A.M., Hartling L., Vandermeer B., McAlister F.A. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. - 2005. - 143:659-672. 33. Clarke R., Halsey J., Lewington S., Lonn E., Armitage J., et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. - 2010. 170:1622-1631.
Klinik protokol Az ərbaycan Respublikas ı S əhiyy
ə Nazirliyinin İctimai S əhi yy
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 67 34. Cohen H.W., Gibson G., Alderman M.H. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. - 2000. 108:2-8. 35. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. - 2004. 364:685-696. 36. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. - 2003. 361:2005-2016. 37. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. - 2003. 24:987-1003. 38. Cooney M.T., Dudina A., De Bacquer D., Wilhelmsen L., Sans S., et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis. - 2009. 206:611-616. 39. Cossette S., Frasure-Smith N., Lesperance F. Clinical implications of a reduction in psychological distress on cardiac prognosis in patients participating in a psychosocial intervention program. Psychosom Med. - 2001. 63:257-266. 40. Critchley J., Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. - 2004. 1: CD003041. 41. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. - 2005. 366:895-906. 42. Dauchet L., Amouyel P., Hercberg S., Dallongeville J.. Fruit and vegetable consumption and risk of coronary heart disease: a meta- analysis of cohort studies. J Nutr. - 2006. 136:2588-2593. 43. De Berardis G., Sacco M, Strippoli G.F., Pellegrini F., Graziano G., et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. - 2009. 339: b4531.
Klinik protokol Az ərbaycan Respublikas ı S əhiyy
ə Nazirliyinin İctimai S əhi yy
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 68 44. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, et al. Earlyintensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. - 2004. - 292:1307-1316. 45. Denollet J., Gidron Y., Vrints C.J., Conraads V.M. Anger, suppressed anger, and risk of adverse events in patients with coronary artery disease. Am J Cardiol. - 2010. 105:1555-1560. 46. Denollet J., Schiffer A.A., Spek V. A general propensity to psychological distress affects cardiovascular outcomes: evidence from research on the type D (distressed) personality profile. Circ Cardiovasc Qual Outcomes. - 2010. 3:546-557. 47. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev. - 2007. -3:CD001820. 48. Di Francescomarino S., Sciartilli A., Di Valerio V., Di Baldassarre A., Gallina S. The effect of physical exercise on endothelial function. Sports Med. - 2009. 39:797-812. 49. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. - 2004. - 364:331-337. 50. Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ. - 1994. 309:901-911. 51. Drew B.S., Dixon A.F., Dixon J.B. Obesity management: update on orlistat. Vasc Health Risk Manag. - 2007. 3:817-821.1701e Joint ESC Guidelines. 52. Duckworth W., Abraira C, Moritz T., Reda D, Emanuele N., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. - 2009. 360:129-139. 53. Dusseldorp E., van Elderen T., Maes S., Meulman J., Kraaij V. A meta- analysis of psychoeduational programs for coronary heart disease patients. Health Psychol. - 1999. 18:506-519. 54. Edwards R. The problem of tobacco smoking. BMJ. - 2004. - 328:217- 219. 55. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. - 2007. 369:201-207.
Klinik protokol Az ərbaycan Respublikas ı S əhiyy
ə Nazirliyinin İctimai S əhi yy
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 69 56. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart Journal. - 2012. - 33, 1635- 1701 doi: 10.1093/eurheartj/ehs092 57. European Heart Network. European Cardiovascular Disease Statistics. - 2008 edition. 58. Food and Nutrition Board. Dietary Reference Intakes for Energy, Carbohydrates, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids. Washington DC: National Academies Press. - 2002. 59. Fowkes FG, Murray GD, Butcher I, Heald CL, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. - 2008. - 300:197-208. 60. Fletcher G.F., Balady G.J., Amsterdam E.A., Chaitman B., Eckel R., Fleg J., et al. Exercise standards for testing and training: a statement for healthcareprofessionals from the American Heart Association. Circulation. - 2001. 104:1694-1740. 61. Franklin B.A., Bonzheim K., Gordon S., Timmis GC. Safety of medically supervised outpatient cardiac rehabilitation exercise therapy: a 16 year follow-up. Chest. - 1998. 114:902-906. 62. Franklin B.A. Cardiovascular events associated with exercise. The risk–protection paradox. J Cardiopulm Rehabil. - 2005. 25:189-195 / quiz 196-187. 63. Fruchart JC, Sacks F, Hermans MP, Assmann G, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. - 2008. - 102:p1K- 34K.
64. Garza C.A., Montori V.M., McConnell J.P., Somers V.K., Kullo I.J., Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc. - 2007. - 82:159-165. 65. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA. - 2006. 296:1735-1741. 66. Gibbons R.J., Abrams J., Chatterjee K., Daley J., Deedwania P.C., Douglas J.S., Ferguson T.B. Jr, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. - 2003. 107:149-158.
Klinik protokol Az ərbaycan Respublikas ı S əhiyy
ə Nazirliyinin İctimai S əhi yy
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 70 67. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (consti-tuted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. - 2007. 14 Suppl 2: S1-113. 68. Gurbel PA, Bliden KP, Butler K, Tantry US, et al. Randomized double- blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. - 2009. - 120:2577- 2585. 69. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. - 2001. 344:1608-1621. 70. Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal A, Coupland C. Antidepressants as risk factor for ischaemic heart disease: case–control study in primary care. BMJ. - 2001. 323:666-669. 71. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. - 1991. 86:1119-1127. 72. He F.J., MacGregor G.A. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens. - 2002. 16:f1-770. 73. He FJ, MacGregor GA. Fortnightly review: beneficial effects of potassium. BMJ. - 2001. 323:497-501. 74. He F.J., Nowson C.A., MacGregor G.A. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet. - 2006. 367:320-326. 75. Heidenreich PA., Trogdon J.G., Khavjou O.A., Butler J., Dracup K., Ezekowitz M.D., Finkelstein E.A., Hong Y., Johnston S.C., Khera A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. - 2011. 123:933-944. 76. He J., Vupputuri S., Allen K., Prerost M.R., Hughes J., Whelton P.K. Passive smoking and the risk of coronary heart disease - a meta- analysis of epidemiologic studies. N Engl, J Med. - 1999. 340:920-926. 77. He K., Song Y., Daviglus M.L., Liu K., Van Horn L., Dyer A.R., Greenland P. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation. - 2004. 109:2705-2711.
Klinik protokol Az ərbaycan Respublikas ı S
əhiyy ə Nazirliyinin İctimai S əhi
yy ə v
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 71 78. He K., Song Y., Daviglus M.L., Liu K., Van Horn L., Dyer A.R., Goldbourt U., Greenland P. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke. - 2004. 35:1538-1542. 79. International Agency for Research on Cancer. Tobacco Control: Reversal of Risk After Quitting Smoking. IARC Handbooks of Cancer Prevention, Vol. 11. Lyon: IARC. - 2007. 80. Investigators TCT. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. - 2001. - 345:494-502. 81. Jardine M.J., Ninomiya T., Perkovic V., Cass A., Turnbull F., Gallagher M.P., Zoungas S., Lambers Heerspink H.J., Chalmers J., Zanchetti A. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. - 2010. 56:956-965. 82. Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V., Hester A., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. - 2008. 359:2417- 2428. 83. Jensen J, Blankenhorn DH, KornerupV. Coronary disease in familial hypercholesterolemia. Circulation. - 1967. - 36:77-82. 84. Jousilahti P., Vartiainen E., Tuomilehto J., Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. - 1999. 99:1165-1172. 85. Katon W.J., Lin E.H., Von Korff M., Ciechanowski P., Ludman E.J., Young B., Peterson D., Rutter C.M., McGregor M., McCulloch D. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. - 2010. 363:2611-2620. 86. Kaptoge S., White I.R., Thompson S.G., Wood A.M., et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol. - 2007. 166:867- 879. 87. Kodama S., Saito K., Tanaka S., Maki M., Yachi Y., Asumi M., et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. - 2009. 301:2024-2035. 88. Lancaster T., Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. - 2004. 4: CD000165.
Klinik protokol Az ərbaycan Respublikas ı S
əhiyy ə Nazirliyinin İctimai S əhi
yy ə v
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 72 89. La Rosa JC, Grundy SM, Waters DD, Shear C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. - 2005. - 352:1425-1435. 90. Lawlor D.A., Ebrahim S., Davey Smith G. Sex matters: secular, geographical trends in sex differences in coronary heart disease mortality. BMJ. - 2001. 323:541-545 91. Law M.R., Morris J.K., Wald NJ. Environmental tobacco smoke exposure and ischemic heart disease: an evaluation of the evidence. BMJ. - 1997. 315:973-980. 92. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R.. Age- specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. - 2002. 360:1903-1913. 93. Lightwood J.M., Glantz S.A. Declines in acute myocardial infarction after smoke free laws and individual risk attributable to secondhand smoke. Circulation. - 2009. 120:1373-1379. 94. Linden W., Phillips M.J., Leclerc J.. Psychological treatment of cardiac patients: a meta-analysis. Eur Heart J. - 2007. 28:2972-2984. 95. Linke A., Erbs S., Hambrecht R.. Effects of exercise training upon endothelial function in patients with cardiovascular disease. Front Biosci. - 2008. 13:424-432. 96. Lippi G., Maffulli N. Biological influence of physical exercise on hemostasis. Semin Thromb Hemost. - 2009. 35:269-276. 97. Liu M, Counsell C, Sandercock P. Anticoagulants for preventing recurrence fol-lowing ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. - 2000. - 2:CD00024 98. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. - 1990. 335:765-774. 99. Malik V.S., Popkin B.M., Bray G.A., Despres J.P., Hu F.B. Sugar - sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation. - 2010. 94:1356-1364. 100. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. - 2007. 25:1751-1762. 101. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, PerriD. Primary prevention of cardiovascular mortality and events with statin
Klinik protokol Az ərbaycan Respublikas ı S əhiyy
ə Nazirliyinin İctimai S əhi yy
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 73 treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. - 2008. - 52:1769-1781. 102. Mohr JP, Thompson JL, Lazar RM, Levin B, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. - 2001. - 345:1444-1451. 103. Mollmann H., Liebetrau C., Nef H.M., Hamm C.W. The Swedish paradox: or is there really no gender difference in acute coronary syndromes? Eur Heart J. - 2011. 32:3070-3072. 104. Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. - 2007. 115:1481-1501. 105. Mozaffarian D., Rimm E.B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. - 2006. 296:1885- 1899. 106. Mozaffarian D., Katan M.B., Ascherio A., Stampfer M.J., Willett W.C. Trans fatty acids and cardiovascular disease. N Engl J Med. - 2006. 354:1601-1613. 107. National Institute for Health and Clinical Excellence [Electronic resource]: NICE Public Health Guidance 10. Smoking Cessation Services in Primary Care, Pharmacies, Local Authorities and Workplaces, Particularly for Manual Working Groups, Pregnant Women and Hard to Reach Communities. - 2008. - Available at: http://www.nice.org.uk/nicemedia/pdf/PH010guidance.pdf (04.02.2014) 108. Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev. - 2009. - 2: CD005019. 109. Neaton JD, Blackburn H, Jacobs D, Kuller L, et al. Serum cholesterol level mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med - 1992.- 152:1490-1500. 110. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, et al. Reductions in all-cause, cancer, and coronary mortality in statintreated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. - 2008. - 29:2625-2633. 111. Neter J.E., Stam B.E., Kok F.J., Grobbee D.E., Geleijnse J.M. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. - 2003. 42:878-884. 112. O’Connor C.M., Whellan D.J., Lee K.L., Keteyian S.J., Cooper L.S., .Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, et al.
Klinik protokol Az ərbaycan Respublikas ı S
əhiyy ə Nazirliyinin İctimai S əhi
yy ə v
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 74 Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. - 2009. 301:1439-1450. 113. O’Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., Wolfson S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. - 1999. 340:14-22. 114. Orth-Gomer K., Schneiderman N., Wang H.X., Walldin C., Blom M., Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes. - 2009. 2:25-32. 115. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. - 2008. 358:2560-2572. 116. Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., Billot L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. - 2007. 370:829-840. 117. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardialinfarction: the IDEAL study: a randomized controlled trial. JAMA. - 2005. - 294:2437-2445. 118. Piepoli M.F., Corra U., Benzer W., Bjarnason-Wehrens B., Dendale P., et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil. - 2010. 17:1-17. 119. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta- analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. - 2004. - 328:189. 120. Poirier P., Alpert M.A., Fleisher L.A., Thompson P.D., Sugerman H.J., et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American HeartAssociation. Circulation. - 2009. 120:86-95. 121. Poirier P., Cornier M.A., Mazzone T., Stiles S., Cummings S., et al. Bariatric surgery and cardiovascular risk factors: a scientific statement
Klinik protokol Az ərbaycan Respublikas ı S əhiyy
ə Nazirliyinin İctimai S əhi yy
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 75 from the American Heart Association. Circulation. - 2011. 123:1683- 1701. 122. Poulter N.R., Wedel H., Dahlof B., Sever P.S., Beevers D.G., et al. Role of blood pressure other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. - 2005. 366:907-913. 123. Preis SR, Hwang SJ, Coady S, Pencina MJ, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. - 2009. - 119:1728-1735 124. Prescott E., Hippe M., Schnohr P., Hein H.O., Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. - 1998. 316:1043-1047. 125. Prescott E., Scharling H., Osler M., Schnohr P.. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidemiol Community Health. - 2002. 56:702-706. 126. Raupach T., Schafer K., Konstantinides S., Andreas S.. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. Eur Heart J. - 2006. 27:386-392. 127. Ray KK, Cannon CP, McCabe CH, Cairns R, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. - 2005. -46:1405-1410. 128. Rayner M., Allender S., Scarborough P. Cardiovascular disease in Europe. Eur J Cardiovasc Prev Rehabil. - 2009. - 16 Suppl 2: S43-S47. 129. Rees K., Bennett P., West R., Davey S.G., Ebrahim S. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev. - 2004. 2: CD002902. 130. Richardson C.R., Kriska A.M., Lantz P.M., Hayward R.A. Physical activity and mortalityacross cardiovascular disease risk groups. Med Sci Sports Exerc. - 2004. 36:1923-1929. 131. Rigotti N.A., Pipe A.L., Benowitz N.L., Arteaga C., Garza D., Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. - 2010. 121:221-229.
Klinik protokol Az ərbaycan Respublikas ı S
əhiyy ə Nazirliyinin İctimai S əhi
yy ə v
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 76 132. Roest A.M., Martens E.J., de Jonge P., Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol, 2010. - 56:38-46. 133. Roest A.M., Martens E.J., Denollet J., de Jonge P. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis. Psychosom Med. - 2010. 72:563- 569.
134. Rose G. Sick individuals and sick populations. Int J Epidemiol. - 1985. 14:32-38. 135. Rollman B.L., Belnap B.H., LeMenager M.S., Mazumdar S., Houck P.R., et al. Telephone-delivered collaborative care for treating post- CABG depression: a randomized controlled trial. JAMA, - 2009. - 302:2095-2103. 136. Romero-Corral A., Montori V.M., Somers V.K., Korinek J., Thomas R.J., et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. - 2006. 368:666-678. 137. Rozanski A., Blumenthal J.A., Davidson K.W., Saab P.G., Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol. - 2005. 45:637-651. 138. Rubak S., Sandbaek A., Lauritzen T., Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. - 2005. 55:305-312. 139. Ruilope L.M., Salvetti A., Jamerson K., Hansson L., Warnold I., Wedel H., Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol, - 2001. - 12:218-225. 140. Sacco RL, Diener HC, Yusuf S, Cotton D, et al. Aspirin and extended- release ipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. - 2008. - 359:1238-1251. 141. Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray G.A., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH–Sodium Collaborative Research Group. N Engl J Med. - 2001. 344:3-10. 142. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. - 2006. - 17:2006-2016. 143. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among
Klinik protokol Az ərbaycan Respublikas ı S əhiyy
ə Nazirliyinin İctimai S əhi yy
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 77 262,525 participants in 29 Western prospective studies. Circulation. - 2007. - 115:450-458. 144. Scheinowitz M., Harpaz D. Safety of cardiac rehabilitation in a medically supervised, community-based program. Cardiology. - 2005. 103:113-117. 145. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation, - 2007. - 116:85-97. 146. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. - 2001. - 285:1711-1718. 147. Sehestedt T., Jeppesen J., Hansen T.W., Wachtell K., Ibsen H., et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. - 2010. 31:883-891. 148. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. - 2006. 29:1220-1226. 149. SIGN (Scottish Intercollegiate Guidelines Network) [Electronic resource]: Risk Estimation and the Prevention of Cardiovascular Disease. A National Clinical Guideline. - 2007. Report No. 97. Availabe at: http://www.sign.ac.uk/pdf/sign97.pdf (12.02.2014). 150. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration, mortality. The Whitehall Study. JAMA. - 1992. - 267:70-76. 151. Steenland K. Risk assessment for heart disease and workplace ETS exposure among nonsmokers. Environ Health Perspect. - 1999. 107 // Suppl 6:859-863. 152. Stead L.F., Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. - 2005. 2:CD001007. 153. Stringhini S., Sabia S., Shipley M., Brunner E., Nabi H., Kivimaki M., Singh-Manoux A. Association of socioeconomic position with health behaviors and mortality. JAMA. - 2010. 303:1159-1166. 154. Talbot L.A., Morrell C.H., Fleg J.L., Metter E.J. Changes in leisure time physical activity and risk of all-cause mortality in men and women: the Baltimore Longitudinal Study of Aging. Prev Med. - 2007. 45:169-176. 155. Taylor R.S., Brown A., Ebrahim S., Jolliffe J., Noorani H., et al. Exercise-based rehabilitation for patients with coronary heart disease:
Klinik protokol Az ərbaycan Respublikas ı S
əhiyy ə Nazirliyinin İctimai S əhi
yy ə v
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 78 systematic review and meta-analysis of randomized controlled trials. Am J Med. - 2004. 116:682-692. 156. Theorell T., Emdad R., Arnetz B., Weingarten A.M. Employee effects of an educational program for managers at an insurance company. Psychosom Med. - 2001. 63:724-733. 157. Thompson P.D., Franklin B.A., Balady G.J., Blair S.N., Corrado D., et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the AmericanHeart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. - 2007. 115:2358-2368. 158. Thun M.J., Myers D.G., Day-Lally C., Namboodin M.M., Calle E.E., et al. Age and the exposure-response relationships between cigarette smoking and premature death in Cancer Prevention Study II. Changes in Cigarette-Related Disease Risks and Their Implications for Prevention and Control. Smoking and Tobacco Control Monograph No. 8. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute. - 1997. 383-413. 159. Tipton C.M. ACSM’s Advanced Exercise Physiology. Baltimore, MD: Lippincott Williams & Wilkins. - 2006. 160. Turnbull F., Neal B., Algert C., Chalmers J., Chapman N., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. - 2005. 165:1410-1419. 161. UK Prospective Diabetes Study Group. Effect of intensive blood- glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. - 1998. 352:854-865. 162. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood- glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. - 1998. 352:837-853. 163. US Department of Health and Human Services [Electronic resource]: Physical Activity Guidelines Advisory Committee Report. 2008. - Availabe at: http://www.health.gov/PAguidelines/ Report/ pdf/CommitteeReport.pdf. 312 (12.02.2014). // Richardson CR, Kriska AM, Lantz PM, Hayward RA. Physical activity and mortality across cardiovascular disease risk groups. Med Sci Sports Exerc. - 2004. 36:1923-1929.
Klinik protokol Az ərbaycan Respublikas ı S
əhiyy ə Nazirliyinin İctimai S əhi
yy ə v
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 79 164. US Department of Health and Human Services [Electronic resource]. 2008 Physical Activity Guidelines for Americans. - 2008. Availabe at: http://www.health.gov/paguidelines/pdf/ paguide.pdf (12.02.2014). 165. Vogt M.T., Cauley J.A., Newman A.B., Kuller L.H., Hulley S.B. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270:465–469. 166. Wamala S.P., Mittleman M.A., Schenck-Gustafsson K., Orth-Gomer K. Potential explanations for the educational gradient in coronary heart disease: a population-based case-control study of Swedish women. Am J Public Health. - 1999. 89:315-321. 167. Wald D.S., Law M., Morris J.K., Bestwick J.P., Wald N.J. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. - 2009. 122:290-300. 168. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. - 2009.361:1045-1057. 169. Warren T.Y., Barry V., Hooker S.P., Sui X., Church T.S., Blair SN. Sedentary behaviors increase risk of cardiovascular disease mortality in men. Med Sci Sports Exerc. - 2010. 42:879-885. 170. Wattigney W.A., Mensah G.A., Croft J.B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. - 2003. 108:711-716. 171. Weickert M.O., Pfeiffer A.F. Metabolic effects of dietary fiber consumption and prevention of diabetes. J Nutr. - 2008. 138:439-442. 172. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., et al. Body-mass index and cause-specific mortalityin 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. - 2009. 373:1083-1096. 173. Whooley M.A., de Jonge P., Vittinghoff E., Otte C., Moos R., et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA. - 2008. 300:2379-2388. 174. WHO Study Group on Tobacco Product Regulation TobReg. Waterpipe Tobacco Smoking: Health Effects, Research Needs and Recommended Actions by Regulators. - 2005. 175. Williams P.T. Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc. - 2001. 33:754-761.
Klinik protokol Az ərbaycan Respublikas ı S əhiyy
ə Nazirliyinin İctimai S əhi yy
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı r. 80 176. Williams R.R., Hunt S.C., Heiss G., Province M.A., Bensen J.T., et al. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol. - 2001. 87:129-135. 177. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. - 2007. 357:2001-2015. 178. World Health Organization. Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases. - 2002. Report No. 916.
179. World Health Organization. Obesity: Preventing and Managing the Global Epidemic.Report of a WHO Consultation. World Health Organization Technical Report Series, Report No 894. - 1998. 180. Zanchetti A., Hansson L., Dahlof B., Julius S., Menard J., et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens. - 2002. 20:2301-2307. 181. Zheng W., McLerran D.F., Rolland B., Zhang X., Inoue M., et al. Association between body-mass index and risk of death in more than 1 million Asians.N Engl J Med. - 2011. 364:719-729.
Klinik protokol Az ərbaycan Respublikas ı S
əhiyy ə Nazirliyinin İctimai S əhi
yy ə v
ə İslahatlar M ərk əzind
ə haz ırlanm
ış dı
Yüklə 0,77 Mb. Dostları ilə paylaş:
|